Trackinsight Enterprise, a unified platform for institutional ETF research, analytics, and compliance, is now live. Explore Trackinsight Enterprise →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

The ETF Industry Is Evolving Fast

From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.

Take the survey

›ETF Issuers›Roundhill Investments›OZEM

OZEM

Roundhill GLP-1 & Weight Loss ETF

Active ETF Equity Theme: Tomorrow's Treatments

Not rated

The OZEM Exchange Traded Fund (ETF) is provided by Roundhill Investments. This fund is actively managed; it does not track an index. This share class generates a stream of income by distributing dividends.

$32.22

-$0.0029 (-0.01%) yesterday

1:30 PM 07/23/26 Closed

1D price range

$31.90$32.31

52W price range

$23.60$36.91

YTD Perf.

-5.74%

YTD Flows

Annualized volatility

Fund AuM

€54M

Share class AuM

€54M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

US77926X8829

TER

0.59%

Inception date

5/21/2024

Issuer

Roundhill Investments

Dividend policy

Distributing

Compare similar ETFs

ETF Name	1w perf.
THNR Amplify Weight Loss Drug & Treatment ETF	-1.15%
476070 SAMSUNG Kodex Global Obesity Treatment TOP2 Plus ETF	+1.16%
SBIO ALPS Medical Breakthroughs ETF	-2.35%
CANC Tema Oncology ETF	+0.01%
BBP Virtus LifeSci Biotech Products ETF	-1.32%
HRTS Tema GLP-1, Obesity & Cardiometabolic ETF	-0.20%
BBC Virtus LifeSci Biotech Clinical Trials ETF	-2.81%
MEDX Horizon Kinetics Medical ETF	0.00%
ASD Defiance Autism Impact ETF	-0.27%

API

PerformanceDec 31, 2025 - Jul 22, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 06/30/26

Healthcare

99.56%

Unavailable

0.44%

Latest OZEM news

Ozempic and Weight Loss Drug ETFs Back in Spotlight After Key Earnings Results

Moving Markets · August 12, 2024

FAQ about OZEM

OZEM is a Active ETF. This ETF provides exposure to Other Equities.

OZEM carries a total expense ratio (TER) of 0.59%, indicating the annual cost for holding the fund.

OZEM was introduced to the market on May 21, 2024. It trades on United States

Roundhill GLP-1 & Weight Loss ETF, OZEM, is provided by Roundhill Investments. Learn more about Roundhill Investments here.

OZEM oversees €54M in assets as of July 22, 2026.

OZEM follows a distributing dividend policy, meaning it pays out income to investors. As of July 22, 2026, its 12-month trailing yield was 1.28%.

As of June 30, 2026, OZEM has significant geographic allocations in USA, Denmark and China.

As of June 30, 2026, OZEM focuses largely on Healthcare.

As of June 30, 2026, OZEM holds 24 positions in its portfolio, with 82.24% of assets concentrated in its top 15 holdings.

As of June 30, 2026, OZEM top three holdings include Novo Nordisk A/S, Eli Lilly & Co. and Pfizer Inc..

The base currency of OZEM is USD.

Top 10 holdings

Data as of 06/30/26

Novo Nordisk A/S

13.29%

Eli Lilly & Co.

13.07%

Pfizer Inc.

6.58%

Kailera Therapeutics, Inc.

6.00%

Viking Therapeutics, Inc.

5.84%

CSPC Pharmaceutical Group Ltd.

5.22%

Chugai Pharmaceutical Co., Ltd.

4.53%

Ascletis Pharma, Inc.

3.95%

Zealand Pharma A/S

3.93%

AstraZeneca PLC

3.89%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

The ETF Industry Is Evolving Fast

Roundhill GLP-1 & Weight Loss ETF

FAQ about OZEM

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US